Lusaris launches with $60 million
Gina Vitale
C&EN Global Enterprise November 7, 2022 DOI: 10.1021/cen-10039-buscon17 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Intervention | 5-MeO-DMT |
| Keywords | Depression economics |
| Key points | Lusaris Therapeutics is developing a sublingual formulation of 5-MeO-DMT as a treatment for treatment-resistant depression. |
Abstract
Lusaris Therapeutics has launched with $60 million in series A financing to develop therapies for severe neuropsychiatric and neurological conditions. The start-up says the type of compounds it is developing, serotonergic neuroplastogens, are able to induce favorable neural plasticity. Its lead candidate, for treatment-resistant depression, is a formulation of the psychedelic 5-Methoxy- N , N -dimethyltryptamine (5-MeO-DMT) that is administered as a dissolvable tablet under the tongue. The firm has exclusively licensed fast-dissolving tablet technology from Catalent for the lead candidate.